JPS60130525A - High polymer immunosuppressant obtained from adlay and production thereof - Google Patents
High polymer immunosuppressant obtained from adlay and production thereofInfo
- Publication number
- JPS60130525A JPS60130525A JP58238539A JP23853983A JPS60130525A JP S60130525 A JPS60130525 A JP S60130525A JP 58238539 A JP58238539 A JP 58238539A JP 23853983 A JP23853983 A JP 23853983A JP S60130525 A JPS60130525 A JP S60130525A
- Authority
- JP
- Japan
- Prior art keywords
- immunosuppressant
- clj
- melting point
- molecular weight
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
本発明はハトムギ種子より得られる旨分子免疫抑制剤お
よびその製造法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a molecular immunosuppressant obtained from Coix seed and a method for producing the same.
ハトムギは古来中国および日本において楽用植物として
用りられており、これを含む漢方の処方は化、皮膚病、
腕節リウマチなどの症状に適用きれている。従来、薬効
成分に関する研究としては、種子のアセトン可溶部中に
抗腫瘍性活性kmするCo1xenolideの存在が
報告されて訃す(T、Ukitaet al、; Ch
ern Pharm、Bull、 9 、43−47
(1961) )また根に存在1−るCo1xiolは
血圧降下、鎮痛作用を有するとされている〔小山 二ほ
か;薬学雑誌。Coix barley has been used as a medicinal plant since ancient times in China and Japan, and herbal medicine containing it has been used to treat skin diseases,
It has not been applied to symptoms such as arm rheumatism. Previous research on medicinal ingredients has reported the presence of Colxenolide, which has antitumor activity, in the acetone-soluble part of seeds (T, Ukita et al.; Ch.
Ern Pharm, Bull, 9, 43-47
(1961) ) Also, 1-Colxiol present in the roots is said to have blood pressure lowering and analgesic effects [Koyama, et al.; Pharmaceutical Journal.
75 、702 (1955) 、、 76 、100
2(1956))。75, 702 (1955), 76, 100
2 (1956)).
L2かしながら、これらCo1xenolideやCo
1xiolの薬効ンま上記漢文処方の薬効とは直接には
結びつき離い。However, these Co1xenolide and Co
The medicinal effects of 1xiol are not directly related to the medicinal effects of the above Chinese prescription.
そこで、本発明者は・・トムギを含む漢方処方の薬効が
アレルギー性疾患に関連深いことに着目し、処方構成生
薬の免疫抑制作用について検討した結果、ハトムギ種子
の熱水抽出液中に■型アレルギーの主因であるIgEの
生成を動物実験で顕著に抑制する成分の存在することを
確認し、その活性成分の分* F# Hに努めた結果、
後記の理化学的性質を有する高分子免疫抑制剤作用物質
を見出し、本物質を免疫抑制剤CLJ−100と命名し
た。Therefore, the present inventor focused on the fact that the medicinal effects of Chinese herbal formulas containing red bean seeds are closely related to allergic diseases, and as a result of examining the immunosuppressive effects of the herbal medicines that make up the formula, we found that We confirmed in animal experiments that there is a component that significantly inhibits the production of IgE, which is the main cause of allergies, and as a result of our efforts to reduce the amount of active component*F#H.
A polymeric immunosuppressant agent having the physicochemical properties described below was discovered, and this substance was named immunosuppressant CLJ-100.
本発明は上記の知見に基騒て完成されたものであって、
後記の理化学的性質?有する免疫抑制剤およびイネ科−
・トムギ属に属する植物の種子を熱水抽出し、その抽出
液から限外濾過法により分子量約1万〜30万の成分を
5)画し、該成分から免疫抑制剤C’LJ−100を分
離精製すること金時徴とする免疫抑制剤CLJ−100
の製造法である。The present invention was completed based on the above knowledge, and
Physical and chemical properties mentioned later? Immunosuppressants with and Poaceae-
・Seeds of plants belonging to the genus Atomyx are extracted with hot water, and components with a molecular weight of approximately 10,000 to 300,000 are separated from the extract by ultrafiltration (5), and the immunosuppressant C'LJ-100 is extracted from the components. Immunosuppressant CLJ-100 that can be isolated and purified
This is the manufacturing method.
本発明の免疫抑制剤CLJ−100は次の理化学的性質
をMする。The immunosuppressant CLJ-100 of the present invention has the following physical and chemical properties.
■元素分析;C39,5〜41.0%、5.8〜6,0
チ、N2.5チ以下、灰分O%、
■分子量;約10万(ゲルー過法による)、■融 点;
明確な融点を示さず、200℃以上で炭化する。■Elemental analysis; C39.5-41.0%, 5.8-6.0
H, N2.5 H or less, ash content O%, ■Molecular weight: Approximately 100,000 (by gel filtration method), ■Melting point;
It does not have a clear melting point and carbonizes at temperatures above 200°C.
■比旋光度;〔α]”+126.5° (C=0.1俤
、0OIN−NaOH水溶液、
■紫外線吸収スペクトル;第1図の通シであって、21
8 nm および270 nm 付近に極大吸収を示す
、
■赤外線吸収スペクトル;第2図の通りであって、3.
300−1前後、2940−”′、1150−―に予力
、!!描造に関連ありと見られる吸収を示す。■Specific optical rotation; [α]”+126.5° (C=0.1°, 0OIN-NaOH aqueous solution, ■Ultraviolet absorption spectrum;
3. Infrared absorption spectrum; as shown in Figure 2, showing maximum absorption near 8 nm and 270 nm.
At around 300-1, 2940-'', and 1150--, there is preload and absorption that seems to be related to the depiction.
■溶剤に対する溶解性;水に可溶、有機溶媒に不浴性、
Q)呈色反応;ヨード反応1韓性、
■物質の色、形状;白色無定形9勿質、OD楯含敏;グ
ルコースとして80〜90%(フェノール#L酸法によ
る)、ウロン酸8〜l、6%(カルバゾール硫酸法によ
る)[株]41り酸糖;トリフルオロ酢酸加水分解によ
れば、主としてグルコースを合力、ガラクト
ース、マンノースまたはアラビノース、ガラクチュ四ン
酸が検出され、ウロン酸、アミノ糖は検出されない。■ Solubility in solvents; soluble in water, non-bathable in organic solvents, Q) Color reaction; iodine reaction, 1 Korean, ■ Color and shape of substance: white amorphous, OD shield, sensitive; glucose 80-90% (by phenol #L acid method), 8-1 uronic acid, 6% (by carbazole sulfuric acid method) [Co.] 41 phosphoric acid; according to trifluoroacetic acid hydrolysis, mainly glucose is synthesized, Galactose, mannose or arabinose, and galactutetraphosphoric acid are detected, but uronic acid and amino sugars are not detected.
また、本免反抑制剤CLJ−100は次の生物化学的性
質を有する。In addition, the present immune suppressant CLJ-100 has the following biochemical properties.
■ 急性毒性;2500mり/KyCマウス、腹腔内入
■ マウスに対して、2,4−ジニトロフェニル化ニワ
トリ卵アルブミン抗原によるIgE生成生成層約2程度
以下に抑制する(ラットPCA反応)本発明の免疫抑制
剤CLJ−10Old’誦分子の糖多楯類様物質である
。従って、前記のCo1xenolide +Co1x
enolとは全く具4る。植物より得られる象疫抑制作
用を有する物λとしてはグリチルリチン〔三宅健夫:ア
レルギー10゜131 (1961)ほか〕が知られて
いるが、これは分子量823の低分子物質であって、本
物質と明らか#(J4なる。また、カンゾウ、サイコ、
サルノコシカケ類などにも鳩分子の免疫抑制作用を有す
ることが報告されて込る〔中島松−ほか:第3回祁漢奈
シンポジウム記録98゜(1969) 、 S、Nak
ashima et、al: Proc。■ Acute toxicity: 2500 m/KyC mouse, intraperitoneal injection ■ The present invention suppresses IgE production to less than about 2 layers by 2,4-dinitrophenylated chicken egg albumin antigen (rat PCA reaction). It is a sugar polyshield-like substance of the immunosuppressant CLJ-10Old'. Therefore, the above Co1xenolide +Co1x
Enol is completely different. Glycyrrhizin [Takeo Miyake: Allergy 10゜131 (1961) and others] is known as a substance λ obtained from plants that has a suppressive effect on elephant disease, but this is a low-molecular substance with a molecular weight of 823, and it is different from this substance. Obviously # (J4. Also, licorice, psycho,
It has been reported that pigeon molecules also have an immunosuppressive effect on monkeys and other species [Matsu Nakashima et al.: Record of the 3rd Keihanna Symposium 98° (1969), S. Nak.
Ashima et al.: Proc.
Symp、 WAKAN−YAKU 13 、42 (
1980) ) が、それらは起源植物を異Kt−1免
疫抑制活性も本発明の物質よシはるかに低り。また、結
核菌体中に言まれるペプチドグVカンも免疫抑制作用を
有するが〔中西点治ほか:日本免疫学会総会記録8,7
(1978) 〕、化学的性質を異にする。従って、
・・トムギよシ分離禮製さ九た本免疫抑制剤CLJ−1
00は従来知られていな込納現物質である。Symp, WAKAN-YAKU 13, 42 (
(1980) ), but their Kt-1 immunosuppressive activity is also much lower than that of the substances of the present invention, which differ from the plant of origin. In addition, the peptidogen V-can found in tuberculosis bacteria has an immunosuppressive effect [Tenji Nakanishi et al.: Japanese Society of Immunology General Meeting Record 8, 7
(1978)], with different chemical properties. Therefore,
・・Immunosuppressant CLJ-1 made from isolated red bean sprouts
00 is a previously unknown inclusion substance.
免役抑制剤は一般にアレルギー、自己免役性疾、害など
の予防、治療などの目的で使用されているが、アレルギ
ー性疾患の予防、治療用に用いる」涙金には、IgIi
3のJ)−全特異的忙抑制し、感染予防に重大な役割會
もりIgG、IgMなどは抑制されな込力がユ筐し込。Immunosuppressants are generally used for the prevention and treatment of allergies, autoimmune diseases, and other illnesses.
3.J) - Inhibits all specific activity and plays an important role in preventing infection, such as IgG and IgM.
抗アレルギー剤として広く用いられてhるaill腎ス
テロステロイドホルモンチルリチンなどはすべての免役
グロブリンの生成を抑制するため、長期の使用による副
作用や、他の疾病に対する感染の危険の増大のたCLJ
−100は化学構造的に副腎ステロイドなどとはまった
く異なり、鎌記の動物実験によりI型アレルギーの原因
とされるIgEの生成は顕著に抑制するが、IgGやI
gMなどの他の免疫グロブリンに対する抑制効果は少な
いため、IgEに起因するとされるアレルギー性疾患に
対し、予防および治療効果を有する免疫抑制剤として有
用である。The aill renal steroid hormone cirrhizin, which is widely used as an anti-allergy agent, suppresses the production of all immunoglobulins, so long-term use can cause side effects and increase the risk of infection with other diseases.
-100 is chemically structurally completely different from adrenal steroids, etc., and it significantly suppresses the production of IgE, which is thought to be the cause of type I allergy, according to Kamaki's animal experiments.
Since it has little suppressive effect on other immunoglobulins such as gM, it is useful as an immunosuppressant having preventive and therapeutic effects on allergic diseases thought to be caused by IgE.
本発明で用いられるイネ科ハトムギ縞に騙する植物とし
ては、東南アジア、中国、日本などに産するハトムギが
挙げられる。果皮および植皮を除だ種にはti仁(ヨク
イニン)と称する。Examples of plants used in the present invention that can be deceived by the stripes of Colay of the Poaceae family include Coix of the Grass family, which is grown in Southeast Asia, China, Japan, and the like. The seeds from which the pericarp and skin graft have been removed are called titan seeds.
果皮および植皮を除かないものは皮付き廠蔵仁またはハ
トムギと称して^る。上記以外に日本国内各地に自生す
る野生種ジュズダマか挙げられる。この種子は市場では
用殻と称している。If the pericarp and skin grafts are not removed, it is called huanggi with skin or adlay. In addition to the above, there is also the wild type Juzudama that grows naturally in various parts of Japan. This seed is called husk in the market.
・・トムギは粉砕し、ないと有効成分の抽出効率がbち
じるしく低く、また用殻は表面が特に強固で粉砕も困難
であるので、実用的には精白された意蔦仁を原料として
用いるのが迩しているが、価格が・・トムギに比し高い
ため、ノ・トムギを粉砕して使用してもよい。...The extraction efficiency of the active ingredients is extremely low if the tomato is not crushed, and the surface of the tomato husks is particularly strong and it is difficult to crush, so for practical purposes, refined yitsutane is used as the raw material. It is commonly used as a tomato, but the price is higher than that of otomugi, so you can also use it by crushing otomugi.
上記植物(11!子は本免疫抑制剤CLJ−100の抽
出効率を上げるために、先ず該原料が粉砕さハ、る。粉
砕された種々から本免疫抑制剤CLJ−100を熱水抽
出するに際しては、予めアセトンなどの有機溶剤で処理
するのが好ましい。In order to increase the extraction efficiency of the present immunosuppressant CLJ-100, the above-mentioned plants (11!) are first crushed. When extracting the present immunosuppressant CLJ-100 from the various crushed plants with hot water is preferably treated with an organic solvent such as acetone in advance.
この処理操作は有機溶剤に数日間浸漬するか、あるいけ
60〜80℃で1〜2時間加熱処理することにより行わ
れる。この有機溶剤処理により、前記のCo1xeno
lideなどやその他の油脂成分も同時に除去すること
ができる。This treatment operation is carried out by immersion in an organic solvent for several days or by heat treatment at 60 to 80°C for 1 to 2 hours. By this organic solvent treatment, the above-mentioned Co1xeno
Lide and other oil and fat components can also be removed at the same time.
熱水抽出は、原料の数倍ないし10数倍程度の水で行わ
れる。抽出温度は50〜120℃程贋の温1Wで行える
が、60℃以下では抽出効率が低く、また90℃以上の
高温では、澱粉質の糊化のため、以後の分離精製工程に
はん雑な手1aを要するので、約60〜85℃の温度範
囲で抽出するのが好ましい。抽出時間は、通常2〜4時
間あるいけ1〜2時間づつ2〜3回にわたり水を取シか
えて抽出すればよい。Hot water extraction is performed using water in an amount several to ten times larger than that of the raw material. Extraction can be carried out at a temperature of 50 to 120 degrees Celsius (1W), but extraction efficiency is low below 60 degrees Celsius, and at high temperatures above 90 degrees Celsius, gelatinization of starch may cause contamination in the subsequent separation and purification process. Therefore, it is preferable to extract at a temperature range of about 60 to 85°C. The extraction time is usually 2 to 4 hours, and the water may be replaced 2 to 3 times for 1 to 2 hours each.
このようにして得られた抽出液は、本免疫抑制剤の他に
色累、低分子物質、塩類、澱粉などの多くの物質を含有
するため、これらの不純物を除去すると共に有効成分の
磯縮をするために限外濾過が行われる。限外濾過は高分
子区画が効率よく集められる方法であればいかなる方法
でもよhが、少なくとも分子!、土1万〜3O万の成分
を分画できるよう限外濾過を行えばよめ。The extract obtained in this way contains many substances such as color stains, low-molecular substances, salts, and starch in addition to the present immunosuppressant, so these impurities are removed and the active ingredients are condensed. Ultrafiltration is performed to Ultrafiltration can be any method that efficiently collects polymer fractions, but at least molecules! If you use ultrafiltration to separate out the 10,000 to 30,000 components of soil, you should do it.
限外濾過装置tとしては、例えば本国アミコン社製ダイ
ア70−セル8200型、8400型、東洋科学産業社
装眠外濾過器UE(P−76型、UHP−62型、米国
ミリポア社製ベリコンラボカセットなどが用いられる。Examples of the ultrafiltration device t include Dia 70-Cell 8200 type and 8400 type manufactured by Amicon in Japan, Ultrafilter UE (P-76 type and UHP-62 type manufactured by Toyo Kagaku Sangyo Co., Ltd.), and Vericon Lab manufactured by Millipore in the United States A cassette or the like is used.
限外−過膜としては、例えばアミコン社製XM300型
、Xy1100A型、YMIO型、71%42型、果洋
科学踵業社製ウルトラフィルター0K200.IJK5
0、UKIOlOKlなどが挙げられる。これらの限外
p過膜を装着した限外p過器r組合せて使用される。@
えば、抽出液をXM300’%4で限外σ1遇し、これ
を〕m過しなり分子i30万以上の成分を主とする分画
とこれを通過する分子@ 3 (1万以下の成分を有す
るfJi液とに分++!+iし、該vi液をYMIO膜
で限外沢瀞して、これを通過しない分子量1万〜30万
の成分とする分画ととれを通過する分子&r万以下の成
分を勺するろ液に分画する。Examples of ultrafilter membranes include Amicon's XM300 type, Xy1100A type, YMIO type, and 71%42 type, and Kayo Kagaku Kagyo Co., Ltd.'s Ultra Filter 0K200. IJK5
0, UKIOlOKl, etc. These ultrap filters equipped with ultra p filter membranes are used in combination. @
For example, an extract is subjected to limit σ1 with The VI liquid is separated into the fJi liquid with a YMIO membrane, and the components with a molecular weight of 10,000 to 300,000 that do not pass through this are fractionated and the molecules that pass through the filter are less than &rquo;10,000. The components are separated into a filtrate.
このようにして抽出液から限外r溝法により分画しPC
分子ギl万〜30万の成分全公知の分離、!t1製方法
により本免役抑制剤CLJ−100を分離イ青J列すれ
ばよい。In this way, the extract was fractionated by the ultra-r groove method and PC
Separation of all known components from 10,000 to 300,000 molecules! The present immunosuppressant CLJ-100 may be separated and placed in a blue J column using the t1 production method.
分廖精氾はゲルー過法、イオン交換クロマトグラフ法、
アワイニイテ〜クロマトグラフ法などをガλ宜組合せる
ことにより行われる。Bunliao Jinghui uses gel filtration method, ion exchange chromatography method,
It is carried out by combining various methods such as chromatography and chromatography.
ゲルFJM剤としては、市販の適箔な分画範囲のゲル濾
過剤全使用すれば、分子冴l万〜30万の成分を紫外部
1技収、フェノール硫献法など(・こより611定した
1iJ−飛11こよりθ分画に分けることができる。例
えば、バイオ・ラド社製バイオケルA1ファーマシア製
セファロースCL6Bなどのアガロース系ゲルPffM
剤全用贋ることにより好適に活性成分全分離することが
できる。As a gel FJM agent, if all commercially available gel filtration agents with suitable fractionation ranges are used, components with a molecular strength of 10,000 to 300,000 can be obtained by one technique under ultraviolet light and the phenol sulfurization method (611 determined from It can be divided into θ fractions from 1iJ-11.For example, agarose-based gel PffM such as Bio-Rad's Biokel A1 and Pharmacia's Sepharose CL6B.
By counterfeiting the entire active ingredient, the active ingredient can be completely separated.
イオン父換クロマトグラフ・イーヲ行う場合には、ファ
ーマシア製C↓哲セファロース、東洋留達社mcMトヨ
バールなどの14イオン交侠体テは活性成分は殆んど吸
着されずに通過するが、陰イオン交換体、例えばファー
マシア製DEAE−セファロース、バイオ拳ラド社HD
EkE〕くイオゲル、東洋W達社MDEAE−トヨノく
〜ルなどでは活性成分は河描なpHにおいて吸着され、
続りで溶出緩所液に食塩を添加すると、その一定濃度の
範囲で溶出される。When performing ion exchange chromatography, 14 ion exchangers such as Pharmacia's C↓ Tetsu Sepharose and Toyo Rudatsusha's mcM Toyovar pass through without being adsorbed, but the negative Ion exchanger, e.g. DEAE-Sepharose manufactured by Pharmacia, Bioken Rad HD
The active ingredients are adsorbed at a moderate pH in EkE]kuyogel, Toyo Wtasha MDEAE-Toyonokuru, etc.
Subsequently, when salt is added to the elution buffer, the salt is eluted within a certain concentration range.
ゲルE過法、イオン交換クロマトグラフ法のいずれの方
法で借らルる4出1&は、通常275nmの紫外酸吸収
および(または)フェノール(plt酸法により測定し
た糖は全mlり定し1、その値に応じて数フラクション
に分画することができる。The amount of sugar measured by either the gel E filtration method or the ion exchange chromatography method is usually 275 nm ultraviolet acid absorption and/or phenol (sugar measured by the PLT acid method). , it can be fractionated into several fractions depending on its value.
同一分画の暦出液は混合し、減圧餠稲踵ゲルp過、透析
など任慧の方法で塩類、緩衝欣成分を除去し、凍結乾燥
することにより所望の免疫抑制剤CLJ−100が得ら
れる。通常、上記ケル濾過剤では最初に溶出され、陰イ
オン交換体では父侠)本に吸涜後、0.2M食塩を含む
緩衝液で浴出される。The extracts of the same fraction were mixed, salts and buffer components were removed by Renhui's method such as vacuum filtration and dialysis, and the desired immunosuppressant CLJ-100 was obtained by freeze-drying. It will be done. Usually, the above-mentioned Kel filter agent is eluted first, and the anion exchanger is eluted first, and after being soaked in water, it is washed out with a buffer solution containing 0.2M sodium chloride.
このようにして得られ/辷凭投抑制剤CLJ−1(10
は、請判された状態番でおいては、安定な白色無定形な
物質であり、穂長糖類)求)幼性と考えられる。Obtained in this manner/Slack Throwing Inhibitor CLJ-1 (10
In the claimed state, it is a stable white amorphous substance and is considered to be juvenile.
次に、本免役抑制剤CLJ−100のIgE抑制活性の
測定法について1ドベる。Next, a method for measuring the IgE suppressing activity of the present immunosuppressant CLJ-100 will be described.
l)抑制剤および1gg生成のための抗原投与法試料臥
14.0ノn9、fBl 2.0ノ179、(CI 1
.0 Ilp採取し、それぞれ水2.0 ml VC溶
かし、生後6退会のマウス3群(1群3匹)のr+>腔
内に1匹当りQ、 5 mlずつ投与する。J1イl
1lill 8+与M′は1匹癌シへ群1.0η、8群
0、5 mg、0群0925りlとなる。投与当日また
l−12H後に、2,4−ジニトロフェニル卵アルブミ
ン全マウス1匹当り10μgヲアラムジュバンド4〃l
σ)懸濁液と共に腹腔Vり投与する。対照として試料未
投与の同一マウス1群3匹に同一抗原をアジュバントと
共に投与シ7、抗原投与Lit 14日後にマウスを心
臓穿刺により採血し、3匹分の血液を混合し、絖固醗、
血清を分離して生1+Ii共塩水で10倍、30倍、1
00倍希釈血清とする。l) Inhibitor and antigen administration method for 1gg production
.. 0 Ilp were collected, each dissolved in 2.0 ml of water and 5 ml of Q per mouse was administered into the r+> cavity of 3 groups of mice (3 mice per group) at 6 days of age. J1 Il
1lill 8+ M' gives 1 cancer to group 1.0η, 8 groups 0, 5 mg, 0 group 0925 l. On the day of administration and after 1-12 hours, administer 10 μg of 2,4-dinitrophenyl ovalbumin per mouse to 4 liters of alum duband.
σ) Administer intraperitoneally along with the suspension. As a control, the same antigen was administered together with an adjuvant to the same group of 3 mice that had not been administered the sample. 7. After 14 days of antigen administration, blood was collected from the mice by cardiac puncture, the blood from the 3 mice was mixed,
Separate the serum and dilute it 10x, 30x, 1x with fresh 1 + Ii co-saline solution.
00 times diluted serum.
2)PCA法によるIgEの測定
体重t so、y前後の雄ラットの背面の毛全刈り、そ
の皮肉に上記徒役マウス希釈血(’ff Q、 l I
n1f、(注射する。1匹当り204副所位投与できる
。注射3〜4 時間tli−、ジニトロフェニル卵アル
ブミン抗原■0ηt1%エバンスブルー液10m1K溶
hイした溶液をラツ)1匹当り1 mlづつ尾静脈注射
する。2) Measurement of IgE by PCA method The hair on the back of a male rat before and after body weight t so, y was completely shaved, and ironically, the diluted blood of the above-mentioned labor mouse ('ff Q, l I
n1f, (Inject. 204 subsites can be administered per animal. Injection 3-4 hours tli-, dinitrophenyl egg albumin antigen ■0ηt 1% Evans blue solution 10ml 1K solution dissolved in rats) 1ml per animal Inject into the tail vein.
注射30分汝、ラットをクロロホルム麻酔死させ、背面
の皮を剥き、轟…1より肯包理の消熱、太き式を測定す
る。抑制剤の効果十分で血77′J中にIgE抗体の仔
在しなり場合は、朋清の各希釈共に6色斑を認めなhが
、抑fIIll剤の効果が弱い場合゛または抑制剤を投
与しない対照マウス血r?jのJ)5合は、血清注射部
位に直径5〜20mm位の顔著な宵色坦が出現する。W
包理の°まったく現わt′Lない場合を4点、有′包理
が注射部周辺に部分的円弧として出功。30 minutes after injection, kill the rat with chloroform anesthesia, peel off the skin on the back, and measure the heat dissipation and thickness of the rat. If the effect of the inhibitor is sufficient and there are no IgE antibodies in the blood, 6-color spots will be observed in each dilution of the serum, but if the inhibitor is weak or the inhibitor is not used. Control mouse blood r? In case J) 5, a marked evening-colored patch with a diameter of about 5 to 20 mm appears at the serum injection site. W
4 points for cases where the inclusion does not appear at all, and 4 points when the inclusion does not appear at all, and the inclusion appears as a partial arc around the injection site.
したものを3点、径10mm以下の青包理を2点、径1
5mm@(lを1点、径20mm以上f:0点のスコア
を与え、同一血清のスコアを合計して判定する。血清各
希釈共まったく−に°包理が見られなり揚台は12点と
なり、全希釈共に20mm以上のd急速を示せは0点と
なる。スコア合計9点以上はかなり卵著に抑制し、8〜
4点は中等度の抑制、3点以下は殆んど抑7ii11な
しと評価する。3 pieces with a diameter of 10 mm or less, 2 pieces with a diameter of 1
5mm @ (1 point for l, 0 points for diameter 20mm or more f: 0 points are given, and the scores for the same serum are totaled to judge. There was no visible embedding at all in each serum dilution, and the lifting platform received 12 points. Therefore, if all dilutions show d-rapidity of 20 mm or more, 0 points will be given.A total score of 9 points or more means that eggs are significantly suppressed, and 8 to
A score of 4 is evaluated as moderate inhibition, and a score of 3 or less is evaluated as almost no inhibition.
仄に実w1例を挙けて、本発明を具体的に説明するが、
これは単なる一例を示すものであって、本姑明全限定す
るものではない。The present invention will be explained in detail with reference to an actual example.
This is merely an example and is not intended to be limiting.
実施例 I
市販の精白ハトムギ(蔵取仁)500g全34谷三角フ
ラスコに容れ、水1.57!を加え、還流冷却器金側し
、浴温85℃の水浴中で3時間加熱した。フラスコを流
水中で冷却し、傾斜により大部分の液分を取り、残渣に
水500m1を〃■えてよく混合し、再び傾斜によp液
分を分離し、た。これを同−谷献の水でさらに2回繰り
返した。全成分全集め、7000 r−p、−mで30
分間遠心分離し、上清1.71を傅た。これをアミコン
社製グイヤフローメンブレンXM300−76を装着し
た東洋科学産業社製限外濾過器UHP−76型に叱し1
.2 Ky71om2の望累気流下で限外濾過を行った
。内液が十分濃縮ざhてから、これに敢借せの槓縛水を
加え、限外p過を反覆し、この操作をさらに2〜3回行
って透11!i物と非透過物を充分に分1lifシた。Example I 500g of commercially available refined pearl barley (Jin Kuratori) was placed in a 34-valley Erlenmeyer flask, and 1.57 g of water was added. was added, the gold side of the reflux condenser was placed, and the mixture was heated for 3 hours in a water bath with a bath temperature of 85°C. The flask was cooled under running water, most of the liquid was removed by decanting, 500 ml of water was added to the residue and mixed well, and the p liquid was separated again by decanting. This was repeated two more times with the same water. All ingredients collected, 7000 r-p, -m at 30
Centrifuge for 1 minute and remove 1.71 minutes of supernatant. This was applied to an ultrafilter UHP-76 model manufactured by Toyo Kagaku Sangyo Co., Ltd. equipped with Guyaflow membrane XM300-76 manufactured by Amicon Corporation.
.. 2 Ultrafiltration was performed under a continuous airflow of Ky71om2. After the internal solution has been sufficiently concentrated, add the extra water to it, repeat the ultrapolar filtration, and repeat this operation 2 to 3 more times to obtain a concentration of 11! The filtrate and non-permeate were thoroughly removed for 1 lif.
最終の非透過物全凍結乾燥して分画fII6557mノ
を得た。透過?(iけこれを合わせ、ダイヤ70−メン
ズレンYMIO−76を装庸した限外濾過器で同様に限
外濾過を行い、非透過物を凍結乾燥して分画(DJ 2
93 mgを得た。透過物はダイヤフローメンブレンY
M2を装眉L7た限外濾過器で限外濾過を行い、非透過
物を凍結乾燥して分画(IID 843 mgを得た。The final retentate was completely lyophilized to obtain fraction fII6557m. Transparent? (Combine these and perform ultrafiltration in the same way using an ultrafilter equipped with Diamond 70-Menstrone YMIO-76, freeze-dry the non-permeate, and fractionate (DJ 2
93 mg was obtained. The permeate is Diaflow Membrane Y
M2 was subjected to ultrafiltration using an ultrafilter fitted with L7, and the non-permeate was lyophilized to obtain a fraction (843 mg of IID).
得られた分画fIl、 IIIおよびΦD各々10g
rnyにっbて、n11記の測定法によりIgE抑制活
1h1]ボした結果は次のとおりであった。10 g each of the obtained fractions fIl, III and ΦD
The results of IgE inhibitory activity (1h1) on rnyb were as follows using the measurement method described in n11.
上記分画のうち最もIgEE生成抑制活性の高い分画1
1.IJ kさらに分141711 Mするため、次の
とおりゲルン濾過を行った。Fraction 1 has the highest IgEE production inhibitory activity among the above fractions
1. To further reduce IJ k to 141711 M, gel filtration was performed as follows.
バイオ・ラド社製バイオゲルA(1,5m(100〜2
00メツシユ)をpM7.6 の0.1 M トリス塩
酸塩緩衝液で平衡化し、カラム(2,6X70α)に充
填し、分+[!1IfH1100m9を同一緩衝液lQ
mlに溶解して加えた。同一の@:衝液で浴出し、浴出
液を201nlづつ分取した。9〜13番目のフラクシ
ョンを集め、減圧WJ縮シフ、透析後、凍結乾燥して白
色無定形の免役抑制剤〔分画[IJFr、1] 25
m9ヲ1仔た。14〜18.#目のフラクションを集め
、前記と回泳に処理し、て僅かに黄褐色無定形物〔分画
(ITlFr、2 ) 10.8 rn&を得た。Fr
、1 およびFr、2のIgE生成抑制活性を測定した
結果は次のとおりであった。Biogel A manufactured by Bio-Rad (1.5m (100-2
00 mesh) was equilibrated with 0.1 M Tris-HCl buffer at pM 7.6 and loaded onto a column (2,6X70α) for minutes + [! 1IfH1100m9 in the same buffer lQ
ml and added. It was bathed with the same @: buffer solution, and the bath solution was collected in 201 nl portions. The 9th to 13th fractions were collected, subjected to reduced pressure WJ Schiff, dialyzed, and lyophilized to obtain a white amorphous immunosuppressant [fraction [IJFr, 1] 25
There was one m9 child. 14-18. The ## fractions were collected and processed to give a slightly yellow-brown amorphous substance (fraction (ITlFr, 2) 10.8 rn&). Fr.
The results of measuring the IgE production inhibitory activity of , 1 and Fr, 2 were as follows.
実施例 2
市販の殻付ノ・トムギ500gをコーヒーミルを用いて
粗く粉砕し、水21を加え、浴温80℃の水浴中で4時
間加熱抽出した。抽出後、実施例1記載と同様に処理踵
分画fl17343ダ、分画(III528〜および分
画[D6777119を得た。各分画の■gE生成抑制
活性を測定した結果は次のとおりであった。Example 2 500 g of commercially available shelled oatmeal was coarsely ground using a coffee mill, water 21 was added thereto, and the mixture was extracted by heating in a water bath at a bath temperature of 80° C. for 4 hours. After extraction, the heel fraction fl17343, fraction (III528~) and fraction [D6777119 were obtained in the same manner as described in Example 1. The results of measuring the gE production inhibitory activity of each fraction were as follows. Ta.
DEkl櫂】トヨパール650MをpH7,6の0.1
Mトリス塩酸塩緩衝液で平衡化し、カラム(0,26X
100crn)に充填し、上記([D分画400 In
9を同一緩衝液29m1に溶解して加えた。同一の緩衝
液320m1.これに0.2Mに食塩を加えたも)40
0In30.5Mに加えたもの400ral、 1.0
Mに加えたもの600 mgでj@次浴出し、1容出I
没は2Qmlずつ試験管に分取した。次いで各試験′d
の275nmにおけるUV吸収、フェノール(liFC
tl法による8i!itをd111定[2、その値に応
じ次の4つのフラクションに別け、rrk忙減圧睦縮、
透析、凍結乾燥りまた。DEkl Kai] Toyo Pearl 650M at pH 7.6 0.1
Equilibrate with M Tris-HCl buffer and load the column (0,26X
100 crn) and the above ([D fraction 400 In
9 was dissolved in 29 ml of the same buffer and added. 320 ml of the same buffer. Added 0.2M salt to this) 40
0In30.5M plus 400ral, 1.0
600 mg of what was added to M @ next bath, 1 volume I
Aliquots of 2Qml each were placed in test tubes. Then each test'd
UV absorption at 275 nm of phenol (liFC)
8i by tl method! It is d111 constant [2, divided into the following four fractions according to its value, rrk busy decompression,
Dialysis and freeze-drying.
1i’r、1 No、7〜21 9.0519Fr、2
No、22〜41 8 0.8 RQFr、3 No
、42〜63 5 6.8 RQFr、4 No、64
〜100 7.2 In&上記の各試料を用いたIgE
抑制能を測定した結果は次のとおりである。1i'r, 1 No, 7-21 9.0519Fr, 2
No, 22-41 8 0.8 RQFr, 3 No.
, 42-63 5 6.8 RQFr, 4 No. 64
~100 7.2 In & IgE using each sample above
The results of measuring the suppressive ability are as follows.
このようにして得た分画上゛r、2の理化学的分析を行
った結果は次のとおりであった。The results of physicochemical analysis of the fraction 1 r, 2 thus obtained were as follows.
元素分析: c 40.95チ、H5,81%、N2.
33チ、灰分0チ、
糖含f:全糖廿ニゲルコースとして91% (フェノー
ル硫酸法)、ウロン酸:ガラク
チュロン酸とし°C1691r(カルバゾールイjff
酸法)、
M h’t 糖ニゲルコース、ガラクトース、マンノー
スまたはアラビノース、ガラクチュロ
ン酸、
比旋光If : (α)” + 126.5°(C=0
.1%、■)
0.01 N −NaOH溶液)、Elemental analysis: c 40.95chi, H5, 81%, N2.
33 g, ash content 0 g, sugar content f: 91% as total sugar content (phenol sulfuric acid method), uronic acid: galacturonic acid °C 1691r (carbazoyl jeff)
Acid method), M h't sugar nigercose, galactose, mannose or arabinose, galacturonic acid, specific rotation If: (α)” + 126.5° (C=0
.. 1%, ■) 0.01 N-NaOH solution),
【図面の簡単な説明】
第1〔初は免疫抑制剤CLJ−100の紫外線吸収スペ
クトル、第2図は免疫抑制剤CLJ −100の赤外線
吸収スペクトルを示す。BRIEF DESCRIPTION OF THE DRAWINGS: 1. The first figure shows the ultraviolet absorption spectrum of the immunosuppressant CLJ-100, and FIG. 2 shows the infrared absorption spectrum of the immunosuppressant CLJ-100.
Claims (1)
0 元素分析; C39,5〜41.0%、H5,8〜6.
0%N2,5チ以下、 灰分0% 分子縫;約10万(ゲルFJ法による)融 点;明確な
融点を示さず、2oo℃以上で炭化する。 比旋光度; ((Z)”+126.5°(C=0.1%
、0.01N−NaOH水溶液) 紫外線吸収スペクトル;第1図ノ通す、扉外If!吸収
スペクトル;第2図の通り、溶剤に対する浴解性;水に
可溶、有機溶剤に不溶性、 呈色反応;ヨード反応陽性、 物質の色、形状;白色無定形物質、 糖含量ニゲルコースとして、80〜90チ(フェノール
硫酸法による)、ウロン酸8〜 16%(カルバゾール硫酸法による)、m成m;トリフ
ルオロ酢酸による加水分解によれば主としてグルコース
を含み、ガラ クトース、マンノースまたはアラビノ ース、ガラクチュロン酸が検出され、 ウロン酸、アミン糖は検出されない。 2) イネ科・・トムギ属に属する植物の種子を熱水抽
出し、その抽出液から限外濾過法により分子量約1万一
30万の成分を分画し5、該成分から免疫抑制剤CLJ
−100を分離精製することを特徴とする免疫抑制剤C
LJ−100の#輩法。 3) イネ科ハトムギ属に属する植物である特許請求の
範囲第2項記載の製造法。 4)熱水抽出を60〜110℃の温度の範囲で行う特許
請求の範囲第2項記載の製造法。 5)分離精製をゲルvEi過法、イオンy侯りロマト法
およびアフィニティークロマト法の一方法またはそれ以
上の方法により行う特許請求の範囲第2項ddIIlf
!の製造法。[Claims] 1) Immunosuppressant CLJ-10 having the following physical and chemical properties:
0 Elemental analysis; C39.5-41.0%, H5.8-6.
0% N2.5 or less, ash 0% Molecular suture; Approximately 100,000 yen (according to gel FJ method) Melting point: Does not show a clear melting point, and carbonizes at temperatures above 20°C. Specific optical rotation: ((Z)”+126.5° (C=0.1%
, 0.01N-NaOH aqueous solution) Ultraviolet absorption spectrum; Figure 1, outside the door If! Absorption spectrum: As shown in Figure 2, bath solubility in solvents: soluble in water, insoluble in organic solvents, color reaction: positive for iodine reaction, color and shape of substance: white amorphous substance, sugar content as nigercose, Hydrolyzed with trifluoroacetic acid, it contains mainly glucose, galactose, mannose or arabinose, galacturonic acid. is detected, but uronic acids and amine sugars are not detected. 2) Seeds of plants belonging to the genus Poaceae (Poaceae) are extracted with hot water, and components with a molecular weight of approximately 11,300,000 are fractionated from the extract using an ultrafiltration method5, and the immunosuppressant CLJ is extracted from these components.
Immunosuppressant C characterized by separating and purifying -100
LJ-100 #person method. 3) The production method according to claim 2, which is a plant belonging to the genus Colay in the family Poaceae. 4) The production method according to claim 2, wherein the hot water extraction is carried out at a temperature range of 60 to 110°C. 5) Separation and purification is carried out by one or more of the gel vEi filtration method, the ion chromatography method, and the affinity chromatography method in Claim 2 ddIIlf
! manufacturing method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58238539A JPS60130525A (en) | 1983-12-17 | 1983-12-17 | High polymer immunosuppressant obtained from adlay and production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58238539A JPS60130525A (en) | 1983-12-17 | 1983-12-17 | High polymer immunosuppressant obtained from adlay and production thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS60130525A true JPS60130525A (en) | 1985-07-12 |
Family
ID=17031751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58238539A Pending JPS60130525A (en) | 1983-12-17 | 1983-12-17 | High polymer immunosuppressant obtained from adlay and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60130525A (en) |
-
1983
- 1983-12-17 JP JP58238539A patent/JPS60130525A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2875308B2 (en) | Method for producing composition containing high concentration of S-allyl cysteine | |
DE3032488C2 (en) | ||
JP2011503186A (en) | A novel extract of Deschampsia antarctica Desv. With antineoplastic activity | |
JP2946183B2 (en) | Perilla extract having TNF production inhibitory action | |
JP4416188B2 (en) | Method for isolating proteinase inhibitor protein from potato tubers | |
JP3071669B2 (en) | Antiallergic substance, method for producing the same, antiallergic agent and functional food | |
FR2633184A1 (en) | ACTIVE INSULATORY PRINCIPLE OF THE BARK OF MIMOSA TENUIFLORA, ITS PREPARATION AND ITS PHARMACEUTICAL APPLICATION | |
AU774836B2 (en) | Protein/polypeptide-K obtained from momordica charantia and a process for the extraction thereof | |
EP0352146B1 (en) | Biological regulator extracted from Gingko Biloba, active in different pathologies. | |
JPS60130525A (en) | High polymer immunosuppressant obtained from adlay and production thereof | |
JP2005502597A (en) | Extract from South Korea | |
US7022349B2 (en) | Antihistamine composition | |
JPH0643330B2 (en) | Barley green juice hypoglycemic agent | |
JP4979053B2 (en) | Anticancer agent containing gentian extract, health supplement and medicinal cosmetic, and method for producing gentian extract | |
JPH03227985A (en) | Simple production of extract with high content of flavonoid from ginkgo leaf | |
JPH03197419A (en) | Substance fractionated from peach leaf and bath liquid containing the same substance | |
KR100527912B1 (en) | anti-allergic an extract manucture method | |
JP2709546B2 (en) | A therapeutic agent for improving tissue disorders due to skin diseases and immune reactions | |
JP2005154322A (en) | Pomegranate rind extract | |
KR20120021030A (en) | Method of manufacturing curcuma aromatica extract a bitter taste removed and curcuma aromatica extract thereof | |
JP3254567B2 (en) | Method for producing physiologically active substance from plant tissue and composition containing this substance | |
CN101415432A (en) | A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereof | |
JPS63297400A (en) | Substance having antiallergic action and its production | |
US20030224067A1 (en) | Antihistamine composition | |
JPS62286926A (en) | Collagenase inhibitor |